Proactive Tacrolimus — SCE Dermatology MCQ

Correct answer: C — The CONTROL trial and others demonstrated that proactive twice-weekly Tacrolimus application to previously affected sites significantly reduces eczema flare frequency compared to reactive (flare-only) treatment

The correct answer is C: The CONTROL trial and others demonstrated that proactive twice-weekly Tacrolimus application to previously affected sites significantly reduces eczema flare frequency compared to reactive (flare-only) treatment. Proactive therapy targets residual subclinical inflammation in skin that looks clinically clear but retains barrier dysfunction and low-grade T-cell activity, which predisposes to relapse. The pivotal 12-month European randomised studies (the basis referred to as the CONTROL trial) showed that twice-weekly 0.1% tacrolimus to previously affected sites significantly prolonged time to first flare and reduced flare frequency compared with vehicle. This proactive, intermittent maintenance approach, applying tacrolimus 0.1% (adults) twice weekly on non-consecutive days, is now standard UK practice once a flare has settled with an initial twice-daily course. Why the other options are wrong: E. BADBIR: This is the British Association of Dermatologists Biologics and Immunomodulators Register, a pharmacovigilance registry for systemic biologic and immunosuppressant therapy (largely psoriasis and other conditions), not a trial of topical calcineurin inhibitor dosing regimens in eczema. B. RITUX 3: This trial evaluated rituximab as first-line therapy in pemphigus vulgaris, an autoimmune bullous disease, and has no relevance to eczema or topical tacrolimus. D. STOP GAP: This UK trial compared prednisolone with ciclosporin for pyoderma gangrenosum, an entirely different condition and treatment class. A. PATCH: This trial investigated antibiotic prophylaxis (penicillin) for prevention of recurrent cellulitis, unrelated to eczema management or TCI dosing strategy. Key point: Proactive twice-weekly tacrolimus 0.1% to previously affected sites, started once an acute flare has cleared with initial twice-daily treatment, is the evidence-based maintenance strategy shown to reduce eczema exacerbation frequency versus reactive flare-only treatment.

Reference: National Eczema Society (UK), Topical Calcineurin Inhibitors (TCIs) factsheet, 2025, https://eczema.org/information-and-advice/treatments-for-eczema/topical-calcineurin-inhibitors/